Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OCUL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cyclosporine 0.1% Ophthalmic Solution | Dry Eye Disease (DED) | N/A · NCT07904728 | Recruiting |
| Tyrvaya | Dry Eye | N/A · NCT07705893 | Recruiting |
| Topical prednisolone acetate | Cataract | Phase 4 · NCT05023304 | Completed |
| Intravitreal injection of axitinib hydrogel… | Non-Proliferative Diabetic Retinopathy | Phase 3 · NCT07235085 | Recruiting |
| OTX-TKI | Neovascular Age-related Macular Degeneration | Phase 3 · NCT06495918 | Active not recruiting |
| Single intravitreal injection of axitinib… | Non-Proliferative Diabetic Retinopathy | Phase 3 · NCT07235085 | Recruiting |
| OTX-TIC high dose Travoprost Intracameral… | Open Angle Glaucoma | Phase 2 · NCT05335122 | Completed |
Also used in these trials (approved or third-party drugs, not OCUL's own candidates): Dexamethasone, Lifitegrast, Prednisolone Acetate, Aflibercept, Bimatoprost.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OCUL holds $530.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $66.4M/quarter from operations, an estimated runway of 24 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 13 · Low
Based on our current operating plan, which includes estimates of anticipated cash inflows from DEXTENZA product sales and cash outflows from operating expenses and capital expenditures and reflects our observance of the minimum liquidity covenant of $20.0 million under the Barings Credit Agreement, we believe that our…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OCUL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 33,160,034 | 15.07% | 2026-09-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 20,850,000 | 9.48% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 15,227,768 | 6.92% | 2026-06-30 |
| Avoro Capital Advisors LLC | Institution (13F) | 12,380,300 | 5.63% | 2026-09-30 |
| SUMMER ROAD LLC | Institution (13G, 5%+) | 12,134,357 | 5.52% | 2025-12-04 |
| Venrock Adviser, LLC | Institution (13F) | 10,346,926 | 4.70% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 8,941,052 | 4.06% | 2026-09-30 |
| Price (T.Rowe) Associates Inc | Institution (13F) | 7,190,029 | 3.27% | 2026-09-30 |
| Logos Global Management LP | Institution (13F) | 6,000,000 | 2.73% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 5,575,452 | 2.53% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 5,273,141 | 2.40% | 2026-09-30 |
| Pravin Dugel Executive Chairman, President and CEO, D |
Insider | 3,270,332 | 1.49% | 2026-08-24 |
Share count 220,022,840 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-06 filed 2026-11-10 |
Sherif Riad |
Award (A) | 28,000 | – | 28,000 |
| 2026-11-06 filed 2026-11-10 |
Sherif Riad |
Option award (A) | 88,000 | – | – |
| 2026-11-05 filed 2026-11-09 |
Saroj Namrata |
Sale (S) | 35,370 | $6.55 | 220,522 |
| 2026-10-08 filed 2026-10-13 |
Anderman Todd |
Sale (S) | 11,984 | $7.29 | 140,484 |
| 2026-10-02 filed 2026-10-06 |
Kaiser Peter |
Sale (S) | 9,990 | $7.05 | 254,388 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCUL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →